Member Info for spike912

Bought at 0.43p, sold at 0.34p stupidly but happy to now buy back at 0.27p, so I’m effect not consolidating a loss luckily Results due soon on the Phase 2 infill trenching at Bibemi with results expected late third quarter 2019; so this month

Jarv55 thanks for the information will take a look, as still researching this one at present on the side lines but thanks for the points in the right direction :-)

Kajo I am not trying to deramp but I will question you when you clearly mislead coming across you have inside information which is either a blatant lie or you are rather silly posting inside information on a monitored board

Kajo,is this fact as your running the risk of inside information on a public board

Sadly as predicted before opening. Read the detail in the RNS and you’ll see why it’s only around 5/6% up. Too much ramping and not enough reading GL all

Just saying. Lots of big sells. Before the market opened I said it would struggle above 0.40 ish, yet some saying 1p plus lol Wonder who looks right

And here comes the sells, people getting impaled here as predicted

Hardy, not at all. I’m not invested here. Looking I’m from sidelines. If you look at the detail you’ll see it’s a £1mil revenue contract, not margin

It’s being ramped without looking at the detail imo

£1mil contract. Revenue is different from margin, i would like to understand profit from the contact No point signing a £1mil contract if your making 5%. Don’t get confused with revenue and profit when assessing mcap

Yes but this isn’t doing 150% today lol Let’s see what we open at first but positive

SL 1p is rather ramptastic imo lol. Maybe 0.40’s 0.50s imo

Well it certainly wasn’t last week of May ;) so you never know with sefton. Could be this week, next week, next month, next year. It’s like roulette

IW although my rebuttal is opinion and not documented over the internet ;-)

I would assume that if the FDA simply ran out of time, the outcome of the Type A meeting would be very indicative to that theory ie passed. The fact we have a likely 3 option outcome, none of which appears a straight approval without conditions, lends me to speculate the FDA did review the drug, and, after such review will recommend either labeling, small trial or post approval monitoring (phase 4). I’m far some saying this won’t be approved but personally and it is imo only, if the theory of “ran out of time” we wouldn’t be in a window of potential approval with conditions/labeling/trials (as per Vox interview). As I say, only my opinion

Smallrader I’m far from looking at an argument but when you quote .... “It's now clear to me that the FDA issued a CRL because it ran out of time to complete its review of the Iclaprim's NDA. Don't ask me how this is possible? It's documented at various places on the internet” You have to be able to show where, it’s documented over the internet in the context of “It's now clear to me that the FDA issued a CRL because it ran out of time to complete its review of the Iclaprim's NDA” That’s all. I wound never gripe at others hard work and research all I am saying is if your making very factual assertions you need to also compete the fact find with the evidence I not do not find that “immature” and clearly I did read so did you I assume, or rather misquoted what my post said Good luck

You have made a clear assertion “It's now clear to me that the FDA issued a CRL because it ran out of time to complete its review of the Iclaprim's NDA. Don't ask me how this is possible? It's documented at various places on the internet” It is clearly not, factually documented over the internet that the FDA issued a CRL because it ran out of time”. It’s your opinion only. That’s all I’m saying, and yes, you may make an education decision, but on speculation not fact I am simply keeping the transparency for potential new investors looking in. Not sure why you have taken it as some kind of personal attack As you say “it’s a discussion board” but you say “keep redirect the cautions/warnings to yourself. Understood?”. Kind of goes against what your saying doesn’t it in regards to an open discussion board

IW Jesus chill. All I’m saying is your posts can be misleading, not sure what why your taking it personally, not your comment “redirect to yourself”, whatever that is meant to allude to!!!

IW, be careful, as your making a pure assumption and speculation at the FDA running out of time. Please remember that’s your view only and not fact

Jamesons, imo I think most are annoyed with yet another missed deadline, and it’s not the first and seems the be the norm For the life of me Sefton never grasps the idea of sentiment. Simply put, he needs to do what any good CEO would do, and either keep the mouth shut or add time. He could have easily said Q3, but he makes a rod for his own back and creates his own critics I can see both sides, and whilst the CPR will come, oil is there, Sefton needs to get a bloody grip of market sentiment and stop failing on promises There is no defending him when he says one thing and delivers another. If he said Q2, or H2, we wouldn’t be having this debate but even I know that narrowing your window to 2 weeks and putting in on an RNS, is a schoolboy error as clearly there could be delays so why make such a statement with such accuracy Nomad should be advising the guy don’t quote dates!